Search Results for: Foster Delivery Science
Articles
2020 COMPANY PROFILES & CAPABILITIES November 27, 2019
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
2/7/2012 February 5, 2012
Foster Analytical Services Speed Time to Market for Drug Delivery Formulations Foster Delivery Science, a business unit for Foster Corporation,...Vetter Becomes Member of the German Association of Research-Based Pharmaceutical Companies (vfa) January 17, 2024
Vetter has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa...SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance September 5, 2023
Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.
Biogen Exercises Option With Denali to Develop & Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta April 12, 2023
Biogen Inc. and Denali Therapeutics Inc. recently announced Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in….
Stevanato Group Collaborates With Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma February 3, 2023
Leading drug containment provider to release a unique offering including both COP and COC pre-fillable syringes (PFS), adding to its existing glass PFS portfolio, providing customers with the broadest choice for PFS….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
Noble Further Expands Capabilities of Its New Human Factors + Program June 9, 2021
In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma company, recently announced the….
Aptar Pharma & Noble Partner With dne pharma on its Nasal Naloxone Treatment March 17, 2021
Aptar Pharma and Noble, an Aptar Pharma company, recently announced their collaboration with dne pharma. Both companies are providing their nasal drug delivery….
Noble & Aptar Pharma Connected Medical Device Solution for Disease Management Adherence & Onboarding Patients October 7, 2020
Noble and Aptar Pharma recently announced the launch of AdhereIT - a connected, intuitive, and user-friendly onboarding solution for the...Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University May 13, 2020
Fortress Biotech, Inc. recently announced that Oncogenuity, Inc. has entered into an exclusive worldwide licensing agreement with Columbia University to develop novel….
EXECUTIVE INTERVIEW - PCI Synthesis: Acquisition by Seqens Expands its Pharmaceutical Offerings April 1, 2019
Ed Price, President and CEO of PCI Synthesis, reflects on the trends fostering the CDMO industry consolidation and the positive impact it augurs in addressing sponsors’ needs to enter the clinic more quickly and safely.
RISK MANAGEMENT - FDA’s Quality Risk Management Approach to New Drug Applications April 1, 2019
Kaiser J. Aziz, PhD, explains how the FDA emphasizes the Quality Risk Management approach to design of studies by providing oversight and objective review of risk-benefit analysis that guides the use of new drug products by providing patients organized data and appropriate labeling information in support of the new drug’s intended clinical use.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: CDMOs Are Innovating for 21st-Century Medicine June 6, 2018
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof.
SPECIAL FEATURE - Challenging Molecules Drive Developers to Get More Creative With Excipients April 2, 2018
Contributor Cindy H. Dubin highlights the techniques various excipient manufacturers are using to develop more innovative and effective ingredients to improve the performance of drug molecules.
FDA UPDATE - The FDA's New Drug Approval Process: Development & Premarket Applications April 2, 2018
Kaiser J. Aziz, PhD, in this latest FDA update, emphasizes quality system approaches to the development and availability of new drug information presented in the proposed labeling of the product.
ORALLY DISINTEGRATING TABLETS - Designed With Patients in Mind: The Art of Patient-Centric Drug Formulation August 30, 2016
Anthony Recupero, PhD, believes by partnering with an expert in drug delivery technology, whose portfolio features a broad range of proprietary technologies, pharmaceutical companies have the potential to add further value to their products and extend market exclusivity.
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables July 12, 2016
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance...MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables July 12, 2016
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance...MilliporeSigma to Develop Next-Generation Purification Processes July 5, 2016
MilliporeSigma has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop more...
